2PQ.F Organogenesis Holdings Inc
- Market cap
- EUR 120M
- P/E
- -
- P/B
- 0.99x
- ROE
- -90.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 2PQ.F undervalued?
Graham numberThe Graham number of Organogenesis Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Organogenesis Holdings Inc fundamental analysis
No fundamental analysis for Organogenesis Holdings Inc yet.
Organogenesis Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Organogenesis Holdings Inc
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin subs…
Full company profileOrganogenesis Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Organogenesis Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 0.00 | 0.00 | 193M | 261M | 338M | 468M | 451M | 433M | 482M | 563M | 166M |
| Gross Profit | -209K | -4.59M | 125M | 185M | 251M | 354M | 346M | 327M | 366M | 426M | 70.9M |
| Operating Income | -209K | -4.59M | -48.1M | -29.5M | 27.4M | 72.9M | 22.3M | 12.5M | 21.5M | 55.9M | -201M |
| EBITDA | - | - | -46.9M | -21.9M | 37.2M | 87.7M | 40.3M | 36.0M | 24.1M | 82.8M | -167M |
| Net Income | -209K | -2.09M | -64.8M | -40.5M | 17.9M | 94.9M | 15.5M | 4.95M | 861K | 37.0M | -239M |
| EPS | - | -0.05 | -0.71 | -0.39 | 0.14 | 0.74 | 0.12 | 0.04 | 0.01 | 0.29 | -1.84 |
| Balance Sheet | |||||||||||
| Total Assets | 311M | 313M | 164M | 221M | 294M | 443M | 449M | 460M | 498M | 599M | 369M |
| Total Liabilities | 11.3M | 14.8M | 117M | 165M | 148M | 201M | 184M | 181M | 113M | 165M | 106M |
| Shareholders' Equity | 300M | 298M | 47.0M | 55.6M | 146M | 242M | 266M | 279M | 385M | 434M | 263M |
| Cash & Short-term Investments | 1.04M | 126K | 21.3M | 60.2M | 84.4M | 114M | 102M | 104M | 136M | 93.7M | 21.3M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -4.87M | -3.49M | -60.6M | -33.5M | 5.47M | 62.0M | 24.9M | 30.9M | 14.2M | -10.3M | -38.8M |
| Capital Expenditure | 0.00 | 2.43M | 1.86M | 5.98M | 17.7M | 31.2M | 33.9M | 24.4M | 10.0M | 14.2M | 7.62M |
| Free Cash Flow | - | -587K | -62.6M | -39.8M | -14.3M | 30.8M | -9.04M | 6.55M | 4.18M | -24.5M | -46.4M |
| Ratios | |||||||||||
| ROE | -0.1% | -0.7% | -137.8% | -72.8% | 12.3% | 39.2% | 5.8% | 1.8% | 0.2% | 8.5% | -90.9% |
| ROA | -0.1% | -0.7% | -39.6% | -18.3% | 6.1% | 21.4% | 3.5% | 1.1% | 0.2% | 6.2% | -64.7% |
| Net Profit Margin | - | - | -33.5% | -15.5% | 5.3% | 20.3% | 3.4% | 1.1% | 0.2% | 6.6% | -143.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Organogenesis Holdings Inc dividends
Organogenesis Holdings Inc has not paid dividends in the last 9 fiscal years.
Who owns Organogenesis Holdings Inc
- Insiders 44.17%
- Institutions 51.55%
- Public & others 4.28%
- Shares outstanding 130M
- Free float 62.2M
Organogenesis Holdings Inc company profile
- Company name
- Organogenesis Holdings Inc
- Ticker
- 2PQ.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 854
- Fiscal year end
- December
- Address
- 85 Dan Road, Canton, MA, United States, 02021
- Phone
- 781 575 0775
- Website
- organogenesis.com
About Organogenesis Holdings Inc
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.
Organogenesis Holdings Inc management
8- Mr. Gary S. Gillheeney Sr.President, CEO, Chair of the Board · born 1955
- Mr. David C. FranciscoChief Financial Officer · born 1966
- Mr. Patrick BilboChief Operating Officer · born 1962
- Ms. Lori H. Freedman B.A., Esq., J.D.Chief Administrative & Legal Officer · born 1967
- Mr. Brian GrowChief Commercial Officer · born 1976
- Mr. Patrick McGuireChief Accounting Officer · born 1986
- Mr. Robert CavorsiChief Business Officer · born 1979
- Mr. William R. Kolb CPASecretary